GI Oncology Daily Digest

High-risk locally advanced rectal cancer carries a substantial risk of distant recurrence, and this multicenter Chinese phase III trial (NCT03177382) asked whether an intensified total neoadjuvant therapy (TNT) regimen could lower that risk. 458 patients with stage II/III disease and at least one high-risk feature (cT4a-b, cN2, mesorectal fascia involvement, or cT3c-d with extramural vascular invasion) were randomized to doublet-LC TNT — induction, concurrent, and consolidation capecitabine plus oxaliplatin integrated with long-course radiotherapy — versus conventional neoadjuvant chemoradiotherapy followed by surgery and adjuvant chemotherapy. At a median 51 months, doublet-LC TNT improved 3-year disease-free survival to 74.8% from 66.0% (HR 0.674, 95% CI 0.489–0.929; p=.016), improved metastasis-free survival (77.7% vs 67.6%; HR 0.655), and nearly tripled the pathologic complete response rate (26.4% vs 9.8%; p<.001), while locoregional failure stayed low and comparable (~6% in both arms). Grade ≥3 adverse events during the neoadjuvant phase were higher with the doublet regimen (27.6% vs 8.6%), but severe toxicity across the whole treatment course (28.0% vs 24.3%) and major postoperative complications (4.0% vs 2.9%) were similar. The authors position doublet-LC TNT as a standard option within the modern TNT paradigm; the open question is how it compares with short-course radiotherapy–based or non-doublet-concurrent TNT regimens rather than against the older conventional chemoradiotherapy backbone used here.

The phase III CHALLENGE trial (CCTG CO.21) already showed that a 3-year structured exercise program (SEP) improved disease-free and overall survival versus health education materials (HEM) in stage III or high-risk stage II colon cancer after surgery and adjuvant chemotherapy. This prespecified economic evaluation, using prospectively collected data from all 889 participants, asks the practical follow-up question payers care about: is it worth paying for? From a Canadian public-payer perspective over a 5-year horizon, it clearly is. Despite an up-front cost of $2,917 CAD per participant to deliver the program, the SEP strategy was actually less expensive overall ($31,957 vs $33,546 CAD; −$1,589 per participant) and more effective (+0.05 life-years and +0.10 quality-adjusted life-years per participant) — a 'dominant' result in health-economic terms. The SEP was dominant in 53% of 1,000 bootstrap samples and fell below a $50,000 CAD/QALY willingness-to-pay threshold in 80%, with the main downstream savings coming from fewer cancer recurrences and less anticancer therapy. Scenario analyses over a 10-year horizon and from a societal perspective (including lost wages) were consistent. The message for health systems is unusual and clean: structured exercise is one of the rare oncology interventions that improves survival while saving money, which strengthens the case for funding and reimbursing it as part of routine survivorship care.

This is the biomarker-focused counterweight to the growing enthusiasm for adjuvant aspirin in colorectal cancer. The parent ASCOLT trial randomized 1,587 patients to aspirin versus placebo and found no significant disease-free survival (DFS) benefit overall; the two other modern trials (including ALASCCA) that did show benefit did so specifically in PI3K-pathway-altered tumors, so this preplanned translational analysis tested whether ASCOLT's own tissue told the same story. Among 397 tumors assessable for PIK3CA, aspirin was NOT significantly associated with improved DFS in any molecularly defined subgroup: PIK3CA mutation of any exon (HR 0.93, 95% CI 0.35–2.47), exon 9/20 mutations specifically (HR 0.72, 0.21–2.46), PIK3CA or PTEN mutation (HR 1.23, 0.47–3.19), or COX-2/PTGS2 overexpression, present in 69% of tumors (HR 0.99, 0.60–1.63) — though every estimate carried wide confidence intervals because the mutant subgroups were small (only 69 patients had any PIK3CA mutation). The pivotal result is the accompanying meta-analysis: pooling the three completed adjuvant-aspirin trials in patients with PIK3CA exon 9/20 mutations yielded a significant reduction in DFS events (HR 0.61, 95% CI 0.39–0.96). The practical read is nuanced — ASCOLT alone was underpowered to confirm the biomarker signal and should not be over-interpreted as negating it, while the pooled data continue to point specifically to exon 9/20 PIK3CA mutation as the group most likely to benefit from a cheap, widely available drug. It sharpens, rather than settles, who should be offered adjuvant aspirin.

PIK3CA is mutated in roughly 15% of colorectal cancers, and because PI3K signaling shapes anti-tumor immunity, there was a plausible hypothesis that adding a PI3K inhibitor to checkpoint blockade might crack the near-total resistance of microsatellite-stable (MSS) colorectal cancer to immunotherapy. This phase 1/2 trial (NCT03711058) tested copanlisib (a PI3K inhibitor) plus nivolumab in metastatic MSS CRC across two cohorts — PIK3CA wild-type (n=17) and PIK3CA-mutant (n=22). The combination was well tolerated, but the primary endpoint of objective response at 6 months was not met in either arm: 0 of 17 wild-type and only 2 of 22 mutant patients responded. Secondary endpoints were uniformly poor and statistically indistinguishable between cohorts — median progression-free survival 1.7 vs 1.6 months and median overall survival 8.5 vs 6.7 months — meaning PIK3CA mutation did not identify a benefiting subgroup. This is a clean negative result worth publishing: it closes off one specific PI3K-plus-anti-PD-1 strategy in unselected MSS CRC and reinforces that overcoming immune resistance in this population will require a fundamentally different approach than simply layering a targeted agent onto PD-1 blockade. The small sample size limits subgroup inference, but the direction of the data is unambiguous.